Los Angeles Capital Management LLC Purchases New Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Los Angeles Capital Management LLC bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 8,895 shares of the company's stock, valued at approximately $1,016,000.

Several other hedge funds also recently bought and sold shares of the stock. Riverview Trust Co purchased a new stake in shares of Vaxcyte during the third quarter valued at approximately $27,000. Fifth Third Bancorp bought a new stake in Vaxcyte in the 2nd quarter valued at about $35,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the period. J.Safra Asset Management Corp raised its position in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after acquiring an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Vaxcyte during the 2nd quarter valued at about $70,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on PCVX shares. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a report on Tuesday, September 10th. BTIG Research increased their price target on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Bank of America increased their price objective on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Needham & Company LLC reissued a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Stock Down 6.3 %

NASDAQ:PCVX traded down $5.85 during mid-day trading on Friday, reaching $86.83. 4,629,278 shares of the company were exchanged, compared to its average volume of 885,972. The stock has a market cap of $10.82 billion, a PE ratio of -18.88 and a beta of 1.01. Vaxcyte, Inc. has a 12 month low of $48.24 and a 12 month high of $121.06. The company has a fifty day moving average of $110.67 and a 200 day moving average of $88.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the business posted ($0.91) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 10,000 shares of the company's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the completion of the transaction, the chief operating officer now directly owns 207,503 shares of the company's stock, valued at $23,225,810.79. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $37,822,574.24. This represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 117,464 shares of company stock worth $12,640,276. Insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.